Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
CaMKII alpha/beta, p Thr286, p Thr287 Antibody (22B1), DyLight 550, Novus Biologicals™

Mouse Monoclonal Antibody
Supplier: Novus Biologicals NB11096869R
Description
CaMKII alpha/beta Monoclonal specifically detects CaMKII alpha/beta in Human, Mouse, Rat samples. It is validated for Western Blot, ELISA, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin, Immunoblotting.Specifications
CaMKII alpha/beta (p Thr286) | |
Monoclonal | |
DyLight 550 | |
50mM Sodium Borate with 0.05% Sodium Azide | |
calcium/calmodulin-dependent protein kinase (CaM kinase) II alpha, calcium/calmodulin-dependent protein kinase II alpha, calcium/calmodulin-dependent protein kinase II alpha-B subunit, CaM kinase II alpha subunit, CaM kinase II subunit alpha, CAMKAcalcium/calmodulin-dependent protein kinase type II subunit alpha, CaMK-II alpha subunit, CaMK-II subunit alpha, CaMKIINalpha, CaM-kinase II alpha chain, EC 2.7.11, EC 2.7.11.17, KIAA0968calcium/calmodulin-dependent protein kinase type II alpha chain | |
Mouse | |
Protein G purified | |
Phospho Specific, Protein Kinase, Signal Transduction, Tyrosine Kinases, Wnt Signaling Pathway | |
815 | |
Human, Mouse, Rat | |
Purified |
Western Blot, ELISA, Immunohistochemistry, Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Paraffin), Immunoblot | |
22B1 | |
Western Blot, ELISA, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin, Immunoblotting | |
P11275 | |
CAMK2A | |
Synthetic peptide | |
0.1 mL | |
Primary | |
This antibody is specific for a and B subunits of CaMKII only when they are phosphorylated at Thr-286/287 (in B). | |
Store at 4C in the dark. | |
IgG1 |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction